Eupraxia Pharmaceuticals
(NASDAQ) EPRX
Eupraxia Pharmaceuticals Financials at a Glance
Market Cap
$436.67M
Revenue (TTM)
$0.00
Net Income (TTM)
$53.67M
EPS (TTM)
$-0.99
P/E Ratio
-7.16
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$7.10
Volume
258,256
Open
$7.52
Price
$7.10
Volume
258,256
Open
$7.52
Previous Close
$7.10
Daily Range
$7.03 - $7.55
52-Week Range
$2.68 - $9.32
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$7.10
Volume
258,256
Open
$7.52
Previous Close
$7.10
Daily Range
$7.03 - $7.55
52-Week Range
$2.68 - $9.32
EPRX News
EPRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Eupraxia Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
21
CEO
James A. Helliwell, MD
Website
www.eupraxiapharma.comHeadquarters
Victoria, BC V8R 5G4, CA
EPRX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-67%
Return on Capital
-43%
Return on Assets
-40%
Earnings Yield
-13.97%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$436.67M
Shares Outstanding
61.50M
Volume
258.26K
Short Interest
0.00%
Avg. Volume
228.84K
Financials (TTM)
Gross Profit
$331.89K
Operating Income
$53.66M
EBITDA
$53.33M
Operating Cash Flow
$39.86M
Capital Expenditure
$822.26K
Free Cash Flow
$40.69M
Cash & ST Invst.
$110.34M
Total Debt
$211.42K
Eupraxia Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$101.43K
N/A
Gross Margin
0.00%
N/A
Market Cap
$436.67M
N/A
Market Cap/Employee
$13.23M
N/A
Employees
33
N/A
Net Income
$23.28M
-115.6%
EBITDA
$22.42M
-108.5%
Quarterly Fundamentals
Net Cash
$110.13M
+233.4%
Accounts Receivable
$923.44K
+303.5%
Inventory
$0.00
N/A
Long Term Debt
$103.97K
N/A
Short Term Debt
$185.90K
+158.7%
Return on Assets
-40.28%
N/A
Return on Invested Capital
-42.95%
N/A
Free Cash Flow
$13.84M
-130.0%
Operating Cash Flow
$13.57M
-127.1%